🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Discovery of BBO-8520, a First-In-Class Direct and Covalent Dual Inhibitor of GTP-Bound (ON) and GDP-Bound (OFF) KRASG12C | Cancer Discovery | American Association for Cancer Research aacrjournals.org/cancerdiscover…

Always great to hear the original RAScal Channing Der Der Lab at UNC talk about KRAS & KRAS inhibitors. Thanks to Channing and his team for putting together such great overview slides. As of March 2025, there are 45 inhibitors (!) & 160 clinical trials. Absolutely amazing. David S. Hong MD

Wow, 160 clinical trials involving agents targeting RAS/KRAS! Norbert Kraut

EGFR mutation is no more a straightforward story. 3 options in 1L, many options in 2L. perez oliveros #ELCC25

#ELCC25 Ph I Daraxonrasib (RAS-On panRAS inhibitor) in RAS+ NSCLC: - ORR 38% - mPFS 9.8m, mDOR 15.1m - modest tox (diarrhea & rash) - 200mg dose selected for ph III Promising. Delighted Ph III RASolve trial of this agent, coming to 🇮🇪 ESMO - Eur. Oncology CancerTrialsIreland 🌈 @Oncoalert #LCSM

Discovery of AMG 193, an MTA-Cooperative PRMT5 Inhibitor for the Treatment of MTAP-Deleted Cancers | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/ac…

Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd) | Nature Communications idp.nature.com/authorize?resp…

This is how you can make a violin plot with statistics in #tidyplots 🚀 tidyplots.org #rstats #dataviz #phd

T-DXd approval finally expanded also in Europe to patients with HR+/HER2-0 (ultralow) disease or chemo-naive pts. Appealing post-ET option for patients with aggressive disease course. Congrats G Curigliano MD PhD for leading the DB06 trial that backed this approval! astrazeneca.com/media-centre/p…

🧬💡 The EMBL Conference 'Cancer genomics' is now open for registration! Submit your abstract by 13 July and join the community of leading scientists and academic clinicians working on cancer genomics 👩🏾‍🔬👨🏻‍🔬 #EMBLCanGen 🗓️ 11 – 14 November 2025 📍 EMBL Heidelberg and Virtual

Evolution of HER2 testing over 40 yrs. IHC lacks the dynamic range to predict outcomes with T-DXd, yet novel quantitative assays are emerging. We presented data with HS-HER2 to predict T-DXd activity at #ESMO24. More data coming at #ASCO25. Stay tuned. nature.com/articles/s4157…

⭐️With so many KRAS targeted drugs entering clinical trials pleased to share our editorial 👉🏼Ready, Set, Go: Setting Off on the Mission to Target KRAS in Colorectal Cancer 🚀🧬🎯 | JCO Oncology Practice JCO Oncology Practice ASCO OncoDaily ascopubs.org/doi/full/10.12…

The 2025 AACR Annual Meeting is coming up in a few short weeks. This post from the AACR details What to Know Before Heading to #AACR25 taking place in #Chicago April 25-30, 2025: aacr.org/blog/2025/04/0…

KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule Inhibitors | Molecular Cancer Therapeutics | American Association for Cancer Research aacrjournals.org/mct/article/24…

FDA new drug approvals in Q1 2025 tinyurl.com/5n8ak54h Only 7 new drugs were approved by the FDA in Q1, but 2 are potential blockbusters - the sodium channel inhibitor suzetigrine for pain and the TROP2-targeted antibody-drug conjugate datopotamab deruxtecan for breast cancer

The AACR is on #Bluesky, where a lot of the online rigorous and respectful scientific discourse has taken place and grown since November. A lot more to come during the upcoming 2025 AACR Annual Meeting (#AACR25) April 25-30. @theaacr.bsky.social

Great to see our work in the April 2025 issue of Molecular Cancer Therapeutics #KRAS

Drug Development Is Slowing Down After Cuts at the #FDA Agency is missing deadlines and not responding to biotech companies, forcing some to push back clinical trials ~3,500 workers were cut at the FDA, including Chief Medical Officer Dr. Hilary Marston and Dr. Peter Stein, who

Emerging importance of HER3 in tumorigenesis and cancer therapy | Nature Reviews Clinical Oncology nature.com/articles/s4157…

I know #AACR25 is coming up, but the program and roster for AACR Special Conference on #PancreaticCancer in Boston in the fall of 2025 is also up and available.... the attendance at this just keeps growing! Dr. Edna Cukierman, Ph.D. Laura DeLong Wood aacr.org/meeting/aacr-s…